Physician profile
David Jacoboff
NPI 1215957030
$64,198.84
in general payments reported to CMS, 2019-2025
33 companies · $360 in 2025
The $360 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $209 · 2021: $31K · 2022: $31K · 2023: $583 · 2024: $430 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,373.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $61,226.78 | 2021-2024 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $370.68 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $344.91 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.86 | 2019-2025 | Jardiance |
| Amgen INC. | $300.47 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $273.54 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $170.60 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $139.58 | 2019-2025 | General - Therapies, Watchman Flx, Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $120.87 | 2019-2025 | Lifevest |
| Heartflow, INC. | $106.63 | 2022-2025 | Ffrct |
| Abbott Laboratories | $89.07 | 2019-2023 | Mitraclip |
| Sanofi-Aventis U.S. LLC | $86.52 | 2019-2023 | |
| Altathera Pharmaceuticals LLC | $80.20 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $54.01 | 2023 | Farxiga, Andexxa |
| Medtronic Vascular, INC. | $53.42 | 2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $48.95 | 2022-2023 | Eliquis |
| Esperion Therapeutics, INC. | $40.76 | 2024-2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $39.82 | 2023-2025 | Uptravi, Opsumit |
| Zoll Circulation INC | $30.64 | 2021 | |
| Cardinal Health 200 LLC | $29.63 | 2020 | |
| Shockwave Medical, INC | $26.33 | 2021 | |
| Amarin Pharma, INC. | $25.92 | 2021 | |
| Abiomed | $25.20 | 2024 | Impella |
| Medtronic, INC. | $22.76 | 2021 | |
| Daiichi Sankyo INC. | $22.50 | 2023 | Injectafer |
| Cardiovascular Systems INC. | $21.92 | 2019 | |
| Bardy Diagnostics, INC. | $20.00 | 2020 | |
| Siemens Medical Solutions USA, INC. | $19.81 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $19.59 | 2024 | Arcalyst |
| United Therapeutics Corporation | $19.02 | 2021 | |
| Cardiva Medical, INC. | $18.30 | 2021 | |
| Cvrx, INC. | $17.73 | 2022 | |
| Glaxosmithkline, LLC. | $16.82 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jacoboff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.